Consumer healthcare giant Kenvue has launched a global media and creative agency review, the company confirmed today.  

It spends an estimated $1.35 billion on measured media annually, according to agency research firm COMvergence.  

The firm has multiple incumbents including Publicis Media and UM on the media side and FCB and BBDO on the creative side. It wasn’t immediately clear which agencies the client was inviting to pitch or if the firm had hired a search consultant to manage the process. 

The company issued a statement confirming the review: “At Kenvue, we are evaluating every opportunity to reduce complexity, improve execution and accelerate growth. We have initiated an integrated global agency review to advance our modern marketing playbook that positions our iconic brands to win in a data-driven, digitally-enabled world. This initiative is designed to confirm we have the right partners in place to grow our iconic brands and best delight customers and consumers at every step of their journey.”  

Kenvue is the former consumer healthcare division of Johnson & Johnson, which spun the unit off in 2022. Its brands include Tylenol, Band-aid, Listerine, Neutrogena, Aveeno and more.   

Tylenol made headlines recently when President Trump made unproven claims linking the pain reliever brand to autism.  

The Kenvue announcement follows word this week that competitor Bayer has finalized its global agency review, selecting IPG to handle media, creative and production.  

 
This story has been updated.